Doylestown, PA June 18, 2008 - Serigene LLC, a developer of a PCR-based diagnostic testing platform, has appointed Professor Klaus Früh to the Company's Scientific Advisory Board.
"We are pleased to welcome Professor Früh to our Scientific Advisory Board," commented Sergey Ilyin, PhD, Chief Scientific Officer of Serigene. "Given Dr. Früh’s extensive scientific credentials, his addition to our Scientific Advisory Board is a significant step forward as we strengthen the scientific base of Serigene."
About Klaus Früh, Ph.D.
Following undergraduate studies at the University of Konstanz and the University of Heidelberg, Dr. Klaus Früh received his Ph.D. from the University of Heidelberg in 1990 studying the immune response to the malaria parasite. He then spent four years as a postdoctoral fellow: one year at the Center for Molecular Biology in Heidelberg and three years at the Scripps Research Institute in La Jolla, CA where he studied molecular pathways of antigen presentation. Dr. Früh then became a Senior Scientist at the R.W. Johnson Pharmaceutical Research Institute, eventually becoming the Group Leader for Molecular Virology at the same company. During this time he developed research programs in viral immune modulation and in antiviral drug discovery. He joined OHSU in 2000 as an Associate Scientist at the VGTI and as Director of the Gene Microarray Shared Resource. Dr. Früh became full Professor for Microbiology and Immunology in 2006.
About Serigene LLC
Serigene was founded to introduce a rigorous and cutting edge standard in field-testing to the diagnostic community. Serigene has developed a proprietary point of care integrated testing technology consisting of a Real Time PCR reader (RT-reader) with a proprietary Serigene cartridge. The Serigene cartridge has significant advantage over alternatives in terms of flexibility, number of tests, and detection speed. More information about Serigene can be found at the company website at www.serigene.com.